These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1907 related articles for article (PubMed ID: 22343901)

  • 1. IDH mutation impairs histone demethylation and results in a block to cell differentiation.
    Lu C; Ward PS; Kapoor GS; Rohle D; Turcan S; Abdel-Wahab O; Edwards CR; Khanin R; Figueroa ME; Melnick A; Wellen KE; O'Rourke DM; Berger SL; Chan TA; Levine RL; Mellinghoff IK; Thompson CB
    Nature; 2012 Feb; 483(7390):474-8. PubMed ID: 22343901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2-hydroxyglutarate inhibits MyoD-mediated differentiation by preventing H3K9 demethylation.
    Schvartzman JM; Reuter VP; Koche RP; Thompson CB
    Proc Natl Acad Sci U S A; 2019 Jun; 116(26):12851-12856. PubMed ID: 31182575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. (R)-2-Hydroxyglutarate Inhibits KDM5 Histone Lysine Demethylases to Drive Transformation in IDH-Mutant Cancers.
    Gunn K; Myllykoski M; Cao JZ; Ahmed M; Huang B; Rouaisnel B; Diplas BH; Levitt MM; Looper R; Doench JG; Ligon KL; Kornblum HI; McBrayer SK; Yan H; Duy C; Godley LA; Koivunen P; Losman JA
    Cancer Discov; 2023 Jun; 13(6):1478-1497. PubMed ID: 36847506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isocitrate dehydrogenase mutation as a therapeutic target in gliomas.
    Han CH; Batchelor TT
    Chin Clin Oncol; 2017 Jun; 6(3):33. PubMed ID: 28705010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypoxia Induces Production of L-2-Hydroxyglutarate.
    Intlekofer AM; Dematteo RG; Venneti S; Finley LW; Lu C; Judkins AR; Rustenburg AS; Grinaway PB; Chodera JD; Cross JR; Thompson CB
    Cell Metab; 2015 Aug; 22(2):304-11. PubMed ID: 26212717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases.
    Xu W; Yang H; Liu Y; Yang Y; Wang P; Kim SH; Ito S; Yang C; Wang P; Xiao MT; Liu LX; Jiang WQ; Liu J; Zhang JY; Wang B; Frye S; Zhang Y; Xu YH; Lei QY; Guan KL; Zhao SM; Xiong Y
    Cancer Cell; 2011 Jan; 19(1):17-30. PubMed ID: 21251613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine.
    Turcan S; Fabius AW; Borodovsky A; Pedraza A; Brennan C; Huse J; Viale A; Riggins GJ; Chan TA
    Oncotarget; 2013 Oct; 4(10):1729-36. PubMed ID: 24077826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting Isocitrate Dehydrogenase Mutations in Cancer: Emerging Evidence and Diverging Strategies.
    Waitkus MS; Yan H
    Clin Cancer Res; 2021 Jan; 27(2):383-388. PubMed ID: 32883741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting isocitrate dehydrogenase (IDH) in cancer.
    Fujii T; Khawaja MR; DiNardo CD; Atkins JT; Janku F
    Discov Med; 2016 May; 21(117):373-80. PubMed ID: 27355333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.
    Rohle D; Popovici-Muller J; Palaskas N; Turcan S; Grommes C; Campos C; Tsoi J; Clark O; Oldrini B; Komisopoulou E; Kunii K; Pedraza A; Schalm S; Silverman L; Miller A; Wang F; Yang H; Chen Y; Kernytsky A; Rosenblum MK; Liu W; Biller SA; Su SM; Brennan CW; Chan TA; Graeber TG; Yen KE; Mellinghoff IK
    Science; 2013 May; 340(6132):626-30. PubMed ID: 23558169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization.
    Ward PS; Lu C; Cross JR; Abdel-Wahab O; Levine RL; Schwartz GK; Thompson CB
    J Biol Chem; 2013 Feb; 288(6):3804-15. PubMed ID: 23264629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations.
    Jin G; Reitman ZJ; Spasojevic I; Batinic-Haberle I; Yang J; Schmidt-Kittler O; Bigner DD; Yan H
    PLoS One; 2011 Feb; 6(2):e16812. PubMed ID: 21326614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
    Chang S; Yim S; Park H
    Exp Mol Med; 2019 Jun; 51(6):1-17. PubMed ID: 31221981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer.
    Saha SK; Parachoniak CA; Ghanta KS; Fitamant J; Ross KN; Najem MS; Gurumurthy S; Akbay EA; Sia D; Cornella H; Miltiadous O; Walesky C; Deshpande V; Zhu AX; Hezel AF; Yen KE; Straley KS; Travins J; Popovici-Muller J; Gliser C; Ferrone CR; Apte U; Llovet JM; Wong KK; Ramaswamy S; Bardeesy N
    Nature; 2014 Sep; 513(7516):110-4. PubMed ID: 25043045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Registered report: IDH mutation impairs histone demethylation and results in a block to cell differentiation.
    Richarson AD; Scott DA; Zagnitko O; Aza-Blanc P; Chang CC; Russler-Germain DA;
    Elife; 2016 Mar; 5():e10860. PubMed ID: 26971564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid Conversion of Mutant IDH1 from Driver to Passenger in a Model of Human Gliomagenesis.
    Johannessen TA; Mukherjee J; Viswanath P; Ohba S; Ronen SM; Bjerkvig R; Pieper RO
    Mol Cancer Res; 2016 Oct; 14(10):976-983. PubMed ID: 27430238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations.
    Intlekofer AM; Shih AH; Wang B; Nazir A; Rustenburg AS; Albanese SK; Patel M; Famulare C; Correa FM; Takemoto N; Durani V; Liu H; Taylor J; Farnoud N; Papaemmanuil E; Cross JR; Tallman MS; Arcila ME; Roshal M; Petsko GA; Wu B; Choe S; Konteatis ZD; Biller SA; Chodera JD; Thompson CB; Levine RL; Stein EM
    Nature; 2018 Jul; 559(7712):125-129. PubMed ID: 29950729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IDH mutations in cancer and progress toward development of targeted therapeutics.
    Dang L; Yen K; Attar EC
    Ann Oncol; 2016 Apr; 27(4):599-608. PubMed ID: 27005468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation.
    Koivunen P; Lee S; Duncan CG; Lopez G; Lu G; Ramkissoon S; Losman JA; Joensuu P; Bergmann U; Gross S; Travins J; Weiss S; Looper R; Ligon KL; Verhaak RG; Yan H; Kaelin WG
    Nature; 2012 Feb; 483(7390):484-8. PubMed ID: 22343896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas.
    Kohanbash G; Carrera DA; Shrivastav S; Ahn BJ; Jahan N; Mazor T; Chheda ZS; Downey KM; Watchmaker PB; Beppler C; Warta R; Amankulor NA; Herold-Mende C; Costello JF; Okada H
    J Clin Invest; 2017 Apr; 127(4):1425-1437. PubMed ID: 28319047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 96.